Analyst Reco. Fortress Biotech, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
3.100 ^USD	-5.49%		-7.19%	-15.30%

Feb. 23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
Jan. 13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE

25-10-01	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101	CI
25-10-01	Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility	DJ
25-10-01	Fortress Biotech and Cyprium Therapeutics announce an update on the NDA for CUTX-101	RE
24-03-19	Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	MT
23-11-29	Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	MT
23-08-22	B. Riley Trims Fortress Biotech's Price Target to $4 From $6, Keeps Buy Rating	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Fortress Biotech to $5 From $6, Maintains Overweight Rating	MT
22-08-04	Ladenburg Thalmann Starts Fortress Biotech at Buy With $6 Price Target	MT
22-07-14	B. Riley Securities Lowers Fortress Biotech's Price Target to $6 from $8, Keeps Buy Rating	MT
22-03-29	Benchmark Capital Adjusts Fortress Biotech's Price Target to $5 from $8, Keeps Buy Rating	MT
21-06-17	FORTRESS BIOTECH : B. Riley Lowers Fortress Biotech's PT to $8 from $9, Says Incremental Pipeline Updates Suggest Heightened Focus on Next-Gen Therapies; Keeps Buy Rating	MT
21-04-20	FORTRESS BIOTECH : Roth Capital Adjusts Price Target on Fortress Biotech to $5 From $4.50, Maintains Buy Rating	MT
21-04-05	FORTRESS BIOTECH : B. Riley Raises Fortress Biotech's Price Target to $9 from $8 After 'Strong' Q4 2020 Results, Keeps Buy Rating	MT